Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:42:46 2025-01-16 am EST			5-day change	1st Jan Change
20.74 ^EUR	+0.05%		+4.97%	+7.38%

Jan. 15	German Stocks Surge as Inflation Data Boost Rate Cut Hopes	MT
Jan. 15	Global markets live: Boeing, Pfizer, Nvidia, Goldman Sachs, Shell...

Jefferies lowers target for Bayer to 22 euros - 'Hold'

November 20, 2024 at 07:21 am EST

NEW YORK (dpa-AFX Broker) - The analyst firm Jefferies has lowered its price target for Bayer from 29 to 22 euros and left its rating at "Hold". He had lowered his earnings estimates for 2025/26, especially in the agricultural chemicals business, analyst Charlie Bentley wrote in a study published on Tuesday. With the decline in operating earnings (EBITDA) that he expects, there is a threat of continued moderate cash inflows and a new peak in debt./gl/he

Publication of the original study: 19.11.2024 / 14:25 / ET First transmission of the original study: 19.11.2024 / 14:25 / ET

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------

Go to the original article.
Legal disclaimer

Latest news about Bayer AG

German Stocks Surge as Inflation Data Boost Rate Cut Hopes	Jan. 15	MT
Global markets live: Boeing, Pfizer, Nvidia, Goldman Sachs, Shell...	Jan. 15
Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	Jan. 15	MT
Bayer suffers next PCB defeat in the US – waiting for the highest court in the land	Jan. 15	DP
After Asundexian setback: Bayer optimistic about new blockbusters	Jan. 15	RE
Another setback: Bayer ordered to pay damages in PCB trial	Jan. 15	RE
Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	Jan. 15	MT
Bayer Aktiengesellschaft Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM	Jan. 14
Bayer pharma chief sees no big acquisitions in near future	Jan. 14	RE
Bayer: first participants in AskBio trial	Jan. 14	CF
Bayer continues to focus on revitalizing its pharmaceuticals business in the medium term – no major deals	Jan. 14	DP
Bayer will focus on debt reduction rather than acquisitions in the coming years	Jan. 14	RE
German Stocks Retreat Amid US Rate Jitters	Jan. 13	MT
Bayer to Commence Late-stage Study for Parkinson's Disease Therapy	Jan. 13	MT
Bayer: towards a Phase III study in Parkinson's disease	Jan. 13	CF
Bayer is starting a crucial cell therapy study for Parkinson's disease	Jan. 13	RE
Klinge Biopharma Signs License Deal for Formycon's Eylea Biosimilar	Jan. 13	MT
Farmers see difficult business situation in 2025	Jan. 11	DP
Bayer Announces Positive Topline Results of the Pivotal Phase III Quanti Studies Evaluating the Efficacy and Safety of Gadoquatrane, an Investigational Gadolinium-Based Contrast Agent for Use in Magnetic Resonance Imaging	Jan. 10	CI
Bayer Files Marketing Authorization Applications for New Indication of Finerenone in US, China	Jan. 10	MT
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA®	Jan. 10	CI
Bayer: positive results for an MRI contrast agent	Jan. 10	CF
Bayer's MRI Contrast Agent Meets Primary, Secondary Endpoints in Late-stage Studies	Jan. 10	MT
German Stocks Muted Amid Local Economic Data Focus	Jan. 09	MT
Bayer to Buy Smart Earth Camelina's Oilseed Crop	Jan. 09	MT

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

94,245

Sector

Pharmaceuticals

Calendar

2025-01-21 - UniCredit Kepler Cheuvreux German Corporate Conference

More about the company